Gyre Therapeutics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Gyre Therapeutics, Inc. (GYRE) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $15.03 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-16.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2015-03-16
- Gyre Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2014 was $15.03M, a 12.18% decline from fiscal 2013.
- Gyre Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2013 was $17.11M, a 880.52% increase from fiscal 2012.
- Gyre Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2012 was $1.75M, a 75.90% decline from fiscal 2011.
- Gyre Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2011 was $7.24M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2014-12-31 | $15.03M 10-K · filed 2015-03-16 |
| 2013-12-31 | $17.11M 10-K · filed 2015-03-16 |
| 2012-12-31 | $1.75M 10-K · filed 2014-03-14 |
| 2011-12-31 | $7.24M 10-K · filed 2014-03-14 |
| 2010-12-31 | -$198.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |